In vitro study of dual drug-eluting stents with locally focused sirolimus and atorvastatin release
Within the context of novel stent designs we developed a dual drug-eluting stent (DDES) with an abluminally focussed release of the potent anti-proliferative drug sirolimus and a luminally focussed release of atorvastatin with stabilizing effect on atherosclerotic deposits and stimulating impact on endothelial function, both from biodegradable poly(l-lactide)-based stent coatings. With this concept we aim at simultaneous inhibition of in-stent restenosis as a result of disproportionally increased smooth muscle cell proliferation and migration as well as thrombosis due to failed or incomplete endothelialisation. The especially adapted spray-coating processes allowed the formation of smooth form-fit polymer coatings at the abluminal and luminal side with 70 % respectively 90 % of the drug/polymer solution being deposited at the intended stent surface. The impacts of tempering, sterilization, and layer composition on drug release are thoroughly discussed making use of a semi-empirical model. While tempering at 80 °C seems to be necessary for the achievement of adequate and sustained drug release, the coating sequence for DDES should be rather abluminal–luminal than luminal–abluminal, as reduction of the amount of sirolimus eluted luminally could then potentially minimize the provocation of endothelial dysfunction. In vitro proliferation and viability assays with smooth muscle and endothelial cells underline the high potential of the developed DDES.
KeywordsDrug Release PLLA Release Phase Triflusal Rigid Amorphous Fraction
The authors thank Dalibor Bajer, Peter Littwin, Martin Radtke and Andrea Rohde for expert technical assistance in stent coating, Ramona Krey, Inge Rühl, Janine Schmidt and Martina Schröder for support with stent characterization regarding morphology and layer thickness and the Biotronik SE & Co. KG for the generous supply of metallic stents and balloon catheter. Additionally, Professor Gerhard Hennighausen is acknowledged for his helpful notes and suggestions. Furthermore, financial support by the Bundesministerium für Bildung und Forschung (BMBF) within REMEDIS “Höhere Lebensqualität durch neuartige Mikroimplantate” (FKZ: 03IS2081) is gratefully acknowledged.
- 13.Serruys PW, Ong ATL, Piek JJ, Neumann F-J, Van der Giessen WJ, Wiemer M, Zeiher A, Grube E, Haase J, Thuesen L, Hamm C, Otto-Terlouw PC. EuroIntervention. 2005;1:58–65.Google Scholar
- 25.Sternberg K, Kroemer HK, Schmitz K-P, Weitschies W, Grabow N, Harder C, Littwin P, Bajer D. Device for Coating a Stent and associated Coating Method and Stent Produced According to the Method.Google Scholar
- 30.Vecerina I, Pham V. Automated Coating Apparatus and Method. 2009; US patent WO/2009/065087.Google Scholar
- 31.Tochterman AJ, Fox WJ, Harold N. Selectively coating luminal surfaces of stents. 2011; US patent US 7,867,547 B2.Google Scholar